The defective MEK/ERK signaling pathway and downstream hypomethylation pattern of lymphocytes are crucial for the pathogenesis of systemic lupus erythematosus (SLE). However, the role that the mesenchymal stem cells play in the MEK/ERK signaling pathway and DNA methylation of peripheral blood mononuclear cells (PBMC) from SLE patients remains unknown. In this study, we found that the MEK/ERK signaling pathway of PBMC from SLE patients was activated after the coculture with bone marrow-derived mesenchymal stem cells (BM-MSC) compared with that from the control group. In addition, the expression level of DNA methyltransferase 1 (DNMT1) increased while the levels of CD70, integrin, alpha L (ITGAL), selectin-l, and IL-13 were reduced in PBMC from SLE patients. However, no obvious effect of BM-MSC on PBMC from healthy controls was observed. These findings revealed that BM-MSC might downregulate the expression of methylation-sensitive genes and then suppress the autoactivated PBMC via the MEK/ERK signaling pathway. And it may be one of the mechanisms that BM-MSC ameliorated SLE.
Keyphrases
- signaling pathway
- pi k akt
- systemic lupus erythematosus
- dna methylation
- end stage renal disease
- mesenchymal stem cells
- disease activity
- bone marrow
- cell proliferation
- ejection fraction
- epithelial mesenchymal transition
- induced apoptosis
- newly diagnosed
- chronic kidney disease
- genome wide
- peritoneal dialysis
- gene expression
- poor prognosis
- rheumatoid arthritis
- long non coding rna
- binding protein
- single cell
- nucleic acid